


The OMNI<sup>®</sup> Surgical System is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm’s canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma.<sup>1</sup>


## CODING OVERVIEW

**Canaloplasty / Transluminal Viscodilation**



**CPT 66174:** Transluminal dilation of aqueous outflow canal; without retention of device or stent

**Goniotomy / Trabeculotomy**



**CPT 65820:** Goniotomy

## SIGHT SCIENCES REIMBURSEMENT SUPPORT LINE

- Reimbursement staff are available to help answer coverage, coding and payment questions and provide reimbursement support for the OMNI System (e.g., pre-auth requests, claims assistance, appeals) Monday through Friday, 8am - 5pm CST.
- Support line personnel can be reached at 844.339.8070 or [Reimbursement@SightSciences.com](mailto:Reimbursement@SightSciences.com). Support services are provided in order to assist with patient access to medical technology.

## AMBULATORY SURGERY CENTER

### CANALOPLASTY/TRANSLUMINAL VISCODILATION (TRABECULOTOMY TYPICALLY BUNDLED INTO CANALOPLASTY WHEN PERFORMED CONCOMITANTLY)<sup>2-4</sup>

CPT <sup>3</sup>	Short Description	National Average Payment Rate <sup>5</sup>	Status Indicator <sup>6</sup>	Multiple Procedure Discounting
66174	Translum dil eye canal	\$1,872.33	A2	Y

### TRABECULOTOMY (AB INTERNO)

CPT <sup>3</sup>	Short Description	National Average Payment Rate <sup>4</sup>	Status Indicator <sup>6</sup>	Multiple Procedure Discounting
65820	Goniotomy	\$1,872.33	A2	Y

## HOSPITAL OUTPATIENT

The OMNI® Surgical System is an insertable/implantable device, not a supply item - sterile or otherwise. As with implantable devices that remain in the body at the conclusion of the surgical procedure, payers (e.g., Medicare and commercial health plans) expect facilities to accurately capture and report insertable/implantable device costs for compliance and rate-setting purposes.<sup>7</sup> Hospital outpatient facilities capture and report device costs using the appropriate HCPCS Code and/or Revenue Code depending on the payer requirements and claim form submitted.

**IMPORTANT NOTE:** The code descriptor for CPT 66174 indicates that the procedure is performed “**without retention of device or stent.**” This is an accurate description, as the device used to perform the procedure is not retained in the body post procedure.

### CANALOPLASTY/TRANSLUMINAL VISCODILATION (TRABECULOTOMY TYPICALLY BUNDLED INTO CANALOPLASTY WHEN PERFORMED CONCOMITANTLY)<sup>2-4</sup>

Coding	Short Description	National Average Payment Rate <sup>4</sup>	Status Indicator <sup>6</sup>	C-APC
CPT 66174	Translum dil eye canal	\$3,917.74	J1	5492
HCPCS C1889	Implantable/insertable device, not otherwise classified	-----	N	-----
Rev Code 278	Medical/Surgical Supplies: Other Implants	-----	N/A	-----

### TRABECULOTOMY (AB INTERNO)

Coding	Short Description	National Average Payment Rate <sup>5</sup>	Status Indicator <sup>6</sup>	C-APC
CPT 65820	Goniotomy	\$3,917.74	J1	5492
HCPCS C1889	Implantable/insertable device, not otherwise classified	-----	N	-----
Rev Code 278	Medical/Surgical Supplies: Other Implants	-----	N/A	-----

## CMS GUIDANCE: DEVICE INTENSIVE PROCEDURES

Effective January 1, 2019, The Centers for Medicare and Medicaid Services (CMS) modified the device-intensive criteria to lower the device offset percentage threshold from greater than 40 percent to greater than 30 percent and to allow procedures that involve single-use devices, regardless of whether or not they remain in the body after the conclusion of the procedure, to qualify as device-intensive procedures.<sup>8</sup>

*Facilities should note that AMA CPT Assistant and NCCI edits advise that it is not appropriate to report both 66174 and 65820 when a canaloplasty and goniotomy (ab interno trabeculotomy) are performed on the same eye during the same treatment session. According to CPT Assistant and NCCI edits only 66174 should be reported.<sup>2,3</sup>*

# SAMPLE CLAIM FORM: CANALOPLASTY PROCEDURE AND OMNI DEVICE REPORTING

ABC Hospital 123 Main Street Anytown, MA 44444 9999555555 9999555555				S123456789123 5000055555				4 TYPE OF BILL			
8 PATIENT NAME a Jane Doe				9 PATIENT ADDRESS a 123 Smith Place, Somewhere, MA 44444							
10 BIRTHDATE 10/01/1958		11 SEX F		ADMISSION 01062021		5 FED. TAX NO. 55-1234567		6 STATEMENT COVERS PERIOD FROM 01062021		7 THROUGH 01062021	
Aetna Claims Processing 10 Payment Place No Town, NY 55555				40 CODE a 24 b c d		40 VALUE CODES AMOUNT A3		41 CODE		41 VALUE CODES AMOUNT	
42 REV. CD. 0360		43 DESCRIPTION Translum dil eye canal		44 HC PCS / R RATE / H IPPS CO DE 66174		45 SERV. DATE 01062021		46 SERV. UNITS 1		47 TO TAL CHARGES XXXXXX	
0278		Medical/Surgical Supplies: Other Implants		C1889		01062021		1		XXXXXX	
48 NON-COVER ED CHARGES										49	
PAGE 1 OF 1		CREATION DATE		01102021		TOTALS		XXXXXX		XX	
50 PAYER NAME Aetna			51 HEALTH PLAN ID 9999999			54 PRIOR PAYMENTS Y Y		55 EST. AMOUNT DUE		56 NPI 112222333	
58 INSURED'S NAME Jane Doe			59 INSURED'S UNIQUE ID 12R4567					57 OTHER PRV ID			
63 TREATMENT AUTHORIZATION CODES PD1234567											
68											
69											
HXX.XXXX		HXX.XX									
c. OTHER PROCEDURE CODE		d. OTHER PROCEDURE DATE		e. OTHER PROCEDURE CODE		e. OTHER PROCEDURE DATE		112222333		LAST	
								77 OPERATING		112222333	
								LAST		FIRST	
80 REMARKS		81C a						78 OTHER		NPI	
		b						LAST		FIRST	
		c						79 OTHER		NPI	
		d						LAST		FIRST	

Revenue code 0278 is used to report insertable/implantable devices (e.g., OMNI device)

HCPCS code C1889 is used to report insertable/implantable devices (e.g., OMNI device) that do not have a more specific HCPCS code

The cost of the OMNI device is assigned to the line item for device reporting (i.e., C1889 & 0278)

Prior-Authorization/Pre-Determination Information if applicable

---

<sup>1</sup> U.S. Food & Drug Administration (FDA) Indications for Use [Traditional 510(k) K173332; K201953; K202678]

<sup>2</sup> Surgery: Eye and Ocular Adnexa. *CPT® Assistant*. December 2018, p 9; Surgery: Eye and Ocular Adnexa. *CPT® Assistant*. September 2019, p 12.

<sup>3</sup> CPT Copyright 2020 American Medical Association (AMA). All rights reserved. CPT® is a registered trademark of the American Medical Association.

<sup>4</sup> <https://www.cms.gov/Medicare/Coding/NationalCorrectCodInitEd/NCCI-Coding-Edits>

<sup>5</sup> National Average Payment Rates reflect the total Medicare allowable amount for a covered procedure. Actual payments vary depending on factors such as geographic adjustment, multiple procedure payment reduction, sequestration, patient deductibles, co-insurance, etc.

<sup>6</sup> ASC Status Indicator A2: Surgical procedure on ASC list in CY 2007; payment based on OPPS relative weight, subject to multiple reduction rule. OPPS Status Indicator J1: Hospital Part B services paid through a comprehensive APC. OPPS Status Indicator N: Items and Services Packaged into APC Rates.

<sup>7</sup> Federal Register /Vol. 75, No. 226 /Wednesday, November 24, 2010 /Rules and Regulations, p 71824.

<sup>8</sup> MLN Matters MM11099; Related CR 11099; January 2019 Update of the Hospital Outpatient Prospective Payment System (OPPS), Revised, January 17, 2019 transmittal #R4204cp.

**Disclaimer:** Reimbursement information provided is presented for informational purposes only. This information does not constitute legal or reimbursement advice. Sight Sciences makes no representation or warranty regarding this information or its completeness, accuracy, timeliness, or applicability with any particular patient. Sight Sciences specifically disclaims liability or responsibility for the results or consequences of any actions taken in reliance on this information. Sight Sciences reminds providers of their responsibility to submit accurate and appropriate claims. Laws, regulations and payer policies concerning reimbursement are complex and change frequently. Providers are responsible for making appropriate decisions related to coding and reimbursement submissions. Accordingly, Sight Sciences recommends that customers consult with payers, reimbursement specialists, and/or legal counsel regarding coding, coverage and reimbursement matters.



4040 Campbell Ave Suite 100  
Menlo Park, CA 94025  
[reimbursement@sightsciences.com](mailto:reimbursement@sightsciences.com)  
844.339.8070